An ECL sensing platform and its preparation method and application
By designing an ECL sensing platform based on DNA "and" logic gated switches, combined with UIO-66@AuNPs and DNA strand replacement network, the non-invasive, sensitivity and specificity of bladder cancer diagnosis methods in the prior art is solved. Problem, high sensitivity parallel detection of low concentration miRNAs is achieved, and the specificity and anti-interference of the detection are improved.
Patent Information
- Application Number
- CN202410319422.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-20
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2044-03-20
AI Technical Summary
The existing bladder cancer diagnosis methods have problems of non-invasiveness, sensitivity and specificity, especially when detecting trace miRNAs in complex urine environments, the reliability of existing electrochemiluminescence detection methods is limited, and multi-target detection is detected. The platform has limitations in signal interference and universality.
Design an ECL sensing platform based on DNA "and" logic gated switch, using glass carbon electrodes and UIO-66@AuNPs as sensing substrates, combining the Hp strand, Fc-ssDNA strand and Ru-ss strand to form a complex , Highly sensitive parallel detection of dual targets is achieved through Au-S covalent bonding and signal quenching, and a specific miRNA marker activity detection kit is constructed using a foothold-mediated DNA strand replacement circulating network.
It realizes high sensitivity parallel detection of low-concentration tumor markers, improves detection specificity and anti-interference, has good stability, reproducibility and reproducibility, and is suitable for the detection of complex samples.
Smart Images

Figure CN118222677B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biological detection chemical analysis, and in particular relates to an ECL sensing platform and a preparation method thereof, and application of the platform in preparing a specific miRNA marker activity detection kit. Background Art
[0002] Bladder cancer is one of the top ten most common tumors in the urogenital system in my country. Although the 5-year survival rate of patients is close to 70%, the recurrence rate is high (50%). The high incidence and recurrence rates lead to a large amount of diagnostic and treatment costs. Cystoscopy, the gold standard for diagnosing cancer, is an invasive procedure that may cause bleeding and infection, thus posing an obstacle to routine diagnosis. In addition, urine cytology, considered a mild examination, is also a means of clinical diagnosis of BC. However, its sensitivity in the detection of early bladder tumors is poor, and the diagnostic specificity is often less than 90%, with a false negative rate of 10-40%. In view of the shortcomings of existing diagnostic methods, there is an urgent need to develop a non-invasive, highly sensitive and specific biosensing strategy for early diagnosis and recurrence monitoring of cancer. MicroRNA, also known as miRNA, belongs to a group of non-coding single-stranded RNA molecules with a length between 20 and 25 nucleotides. Recent studies have suggested a potential link between miRNA expression levels and cancer, and notably, specific miRNAs, such as miRNA-21, miRNA-183, and miRNA-96, have been found to be overexpressed in the serum or urine of patients with bladder cancer, suggesting their potential as biomarkers for the diagnosis of this condition. Current detection methods for urinary biomarkers for bladder cancer, such as electrochemical and fluorescent, are limited in their reliability because disease-associated miRNAs are present at very low levels in the complex environment of urine. Therefore, it is critical to develop a highly reliable method for the detection of trace amounts of miRNAs in human urine for the diagnosis and monitoring of bladder cancer before and after surgery.
[0003] Electrochemiluminescence (ECL) is a promising biosensing technology characterized by the chemiluminescence phenomenon caused by the transfer of high-energy electrons caused by electrochemical reactions. ECL technology has several advantages, including minimal background signal interference, high detection sensitivity, and easy operation. It has been widely used in the development of nucleic acid and protein biosensors. However, most ECL biosensors developed in recent years focus on detecting a single target. Previous studies have shown that certain biomarkers tend to show high expression levels in different diseases. Therefore, relying solely on a single biomarker for disease detection may lack specificity and increase the possibility of obtaining false positive results. For example, the patent document CN115032258A-miRNA tumor marker detection kit previously disclosed by our research group can only be used for the detection of a single miRNA tumor marker. This problem remains a key issue in the field of biosensors. Therefore, the development of a multi-target ECL biosensor strategy is of great value because it can screen diseases more accurately and minimize the occurrence of false positives.
[0004] Previous multi-target biosensors have emphasized the importance of using multi-signal probes. Typically, the strategies used in these studies are based on differences in wavelength or luminescence potential to distinguish signals for multi-target detection. For example, Chinese invention patent application CN116297769A discloses a group-selectively functionalized potential-resolved electrochemiluminescent nucleic acid detection method, which uses thiol- and amino-functionalized probe RNA and CdTe NCs for covalent bonding, thereby constructing a potential-resolved ECL sensor based on the same nanomaterial, achieving simultaneous detection of the new coronavirus ORF1ab and N genes. Although the above detection schemes have made some progress, there are still significant limitations, especially in terms of complex assembly and signal interference of the sensing platform, which can reduce the accuracy of the detection. In addition, existing sensing platforms lack sufficient versatility. Summary of the invention
[0005] Existing tumor marker detection methods have technical problems such as expensive instruments, large sample size, complex operation and low detection sensitivity. In order to overcome the above-mentioned deficiencies of the prior art, the present invention provides an ECL sensing platform and a preparation method thereof and its application in the preparation of a specific miRNA marker activity detection kit. Based on ECL electrochemical detection, a DNA "AND" logic gate switch is designed to solve the problem of complex construction of the existing electrochemiluminescence detection dual-target platform, and realize high-sensitivity parallel detection of two tumor markers.
[0006] The technical solution adopted by the present invention is:
[0007] In the first aspect, the present invention provides an ECL sensing platform, namely an electrochemiluminescence sensor based on DNA "AND" logic gate switch, such as Figure 1a As shown, the electrochemiluminescent sensor is composed of a sensing substrate and a DNA "AND" logic gate switch complex loaded on the sensing substrate;
[0008] The sensing substrate is composed of a glassy carbon electrode and a substrate material UIO-66@AuNPs modified on the glassy carbon electrode;
[0009] The DNA "AND" logic gate switch complex is a complex formed by hybridization of an Hp chain, an Fc-ssDNA chain and a Ru-ss chain, wherein the Hp chain is a DNA chain containing a hairpin structure, the Fc-ssDNA chain is a single chain modified with a quenching group ferrocene, and the Ru-ss chain is a single chain modified with a luminescent group Ru(bpy)3 2+ and a single strand of thiol functional groups; the DNA "AND" logic gate switch complex can be specifically opened by two signal activation chains; the thiol functional groups modified on the Ru-ss chain can be loaded on the UIO-66@AuNPs through Au-S covalent bonds, and the ferrocene and the luminescent group Ru(bpy)3 2+ There is a signal quenching effect between them;
[0010] like Figure 1a As shown, the Hp chain is a DNA chain containing multifunctional blocks, which is composed of blocks Hp-1 (yellow), Hp-2 (orange), Hp-3 (red), Hp-4 (orange), Hp-5 (dark blue), and Hp-6 (red). The sequences of blocks Hp-2 and Hp-4 are complementary to each other to form a hairpin structure. The DNA sequence of the Fc-ssDNA chain is complementary to that of block Hp-5, and the DNA sequence of the Ru-ss chain is complementary to that of block Hp-6. Blocks Hp-1 and Hp-2 are complementary to each other. The sequence composed of the activation sequence S1-1 of the activation chain S1 is complementary, so the activation chain S1 can open the hairpin structure of the Hp chain and bind to it. After the hairpin structure of the Hp chain is opened, the blocks Hp-3 and Hp-4 are exposed. The sequence composed of the blocks Hp-4 and Hp-5 is complementary to the activation sequence S2-1 of the activation chain S2, so the activation chain S2 can replace the Fc-ssDNA chain to form a more stable structure with the Hp chain. After the Fc-ssDNA chain modified with ferrocene is replaced, the luminescent group Ru(bpy)3 2+ The ferrocene signal quenching effect is invalid, and the signal of the luminescent group can be detected.
[0011] Preferably, the functional chains containing the DNA sequences are designed as follows: Ru-ss: 5′HS-SH-ATTACGCCGCGA-Ru(bpy)32+ -3′, sequence as SEQ ID NO.1;
[0012] Fc-ss: 5′Ferrocene-GTCAGCAGGGGG-3′, sequence as SEQ ID NO. 2;
[0013] Hp: 5′-CAACTTGGCGGTGGCAACCGCCCCCCCTGCTGACAACGGCGGCG-3′, sequence is SEQ IDNO.3;
[0014] Activation sequence S1-1: ACCGCCAAGTTG, sequence as SEQ ID NO.10;
[0015] Activation sequence S2-1: GTCAGCAGGGGGGGCGGT, the sequence is as SEQ ID NO.11.
[0016] Preferably, the preparation process of the UIO-66@AuNPs complex includes: dissolving terephthalic acid and ZrOCl2·8H2O in NN′-dimethylformamide DMF, then ultrasonically oscillating the mixture, adding acetic acid HAc, heating at 90°C for 18 hours, and then obtaining a UIO-66 solution, then adding 1% concentration of chloroauric acid and 4 mg / mL of sodium borohydride to the solution, and then centrifuging to obtain UIO-66@AuNPs solid, dispersing it in water and storing it at low temperature; the raw material configuration mass ratio of the terephthalic acid and ZrOCl2·8H2O is 50:21, and the raw material configuration mass volume ratio of the terephthalic acid and the dimethylformamide is 50 mg:4mL; the raw material configuration volume ratio of the dimethylformamide and the acetic acid is 2:1; the raw material configuration volume ratio of acetic acid, chloroauric acid and sodium borohydride is 100:1:1.
[0017] The present invention also provides a method for preparing the above-mentioned electrochemiluminescence sensor, wherein in advance, a glassy carbon electrode is polished, ultrasonicated, and cleaned to obtain a clean electrode surface; an aqueous solution of UIO-66@AuNPs is dripped on the electrode, left to stand, and dried at room temperature; then, a TMbuffer solution of a pre-prepared DNA "AND" logic gated switch complex is dripped on the electrode, reacted at 4°C for 8 hours, and the structure is modified on the electrode using an Au-S bond, thereby preparing an ECL sensing platform, wherein the concentration range of the aqueous solution of UIO-66@AuNPs is 0.1 to 8 mg / mL; and further, the concentration of the aqueous solution of UIO-66@AuNPs is preferably 2 mg / mL, and the loaded DNA "AND" logic gated switch complex reaches a saturated state under this concentration condition.
[0018] In a second aspect, the present invention also provides an application of the above-mentioned ECL sensing platform in the preparation of a specific miRNA marker activity detection kit, wherein the detection kit is composed of the above-mentioned ECL sensing platform and a target miRNA signal amplification reagent; the target miRNA signal amplification reagent is a mixed reagent composed of a toehold-mediated DNA strand displacement cycle network;
[0019] The specific miRNA markers described in the present invention are a group of combined markers that can specifically characterize a specific type of disease, which are recorded as the first target miRNA and the second target miRNA, and the sequence length of the first target miRNA and the second target miRNA is within the range of 21-23 bases. For example, miRNA-183 and miRNA-96 are a group of markers that can characterize bladder cancer, and miRNA-21 and miRNA-145-5p are also a group of markers that can characterize bladder cancer. In addition, miRNA-499 and miRNA-133a that have been discovered are a group of markers that can characterize acute myocardial infarction.
[0020] In addition to the activation sequence, the activation chains S1 and S2 also respectively contain a release sequence designed according to the sequence of the target miRNA, which are marked as S1-2 (purple) and S2-2 (light blue), respectively, that is, block S1-2 is designed according to the sequence of the first target miRNA, and block S2-2 is designed according to the sequence of the second target miRNA; accordingly, the target miRNA signal amplification reagent is composed of two groups of signal amplification reagents, the first group of signal amplification reagents is used to amplify the signal of the first target miRNA, and the second group of signal amplification reagents is used to amplify the signal of the second target miRNA; the first group of signal amplification reagents is composed of a first signal detection probe and a first signal amplification probe, the first signal detection probe is a DNA structure m1 / S1 formed by hybridization of m1 and S1, and the first signal amplification probe H1 is a DNA chain with hairpin structures at both ends; accordingly, the second group of signal amplification reagents is composed of a second signal detection probe and a second signal amplification probe, the second signal detection probe is a DNA structure m2 / S2 formed by hybridization of m2 and S2, and the second signal amplification probe H2 is also a DNA chain with hairpin structures at both ends;
[0021] The first signal detection probe and the second signal detection probe specifically respond to two target miRNAs, thereby releasing two signal activation chains S1 and S2; the first signal amplification probe H1 and the second signal amplification probe H2 are respectively complementary to the two single-stranded chains m1 and m2, and can hybridize with S1 and S2 after they are released, thereby releasing the target miRNA; the two large signal activation chains released by the toehold-mediated DNA chain displacement cycle network can specifically open the DNA "AND" logic gate switch;
[0022] like Figure 1b As shown, in the first signal detection probe, the single strand m1 is composed of blocks m1-1, m1-2, and m1-3 in sequence. The sequence m1-1-2 composed of the blocks m1-1 and m1-2 is complementary to S1-1, but the sequence m1-1-2 is slightly longer than S1-1, that is, 4 more bases. After the two are complementary, the sequence m1-1-2 still has a free sticky sequence. The block m1-3 is complementary to S1-2, but the sequence m1-3 is slightly longer than S1-2, that is, 3 more bases. After the two are complementary, the sequence m1-3 still has a free sticky sequence. This design is to facilitate the first target miRNA in the sample to quickly replace the activation chain S1 and form a more stable complex structure with the m1. However, since the single-stranded m1 is designed with only the sequence composed of blocks m1-1 and m1-3 being completely complementary to the first target miRNA, when the first target miRNA block forms a complex with the m1, m1-2 will correspondingly form a neck ring structure, so as to open the gap in the first signal amplification probe H1 that does not form a neck ring structure, that is, the first signal amplification probe H1 is sequentially composed of The composition of blocks H1-1, H1-2 and H1-3, wherein the internal sequences of blocks H1-1 and H1-3 are complementary to each other to form neck loop structures at both ends of H1, and only the middle H1-2 is exposed, which is the gap in the first signal amplification probe H1 where the neck loop structure is not formed, and can be specifically recognized by m1-2. Since blocks H1-1 and H1-3 respectively contain sequences complementary to m1-1 and m1-3, when m1-2 specifically recognizes the gap H1-2 in H1 where the neck loop structure is not formed, the neck loop structures at both ends of the first signal amplification probe H1 can be opened by chain extension so that H1 replaces the first target miRNA and combines with m1 to form a more stable structure, thereby re-releasing the first target miRNA. The released first target miRNA can react with a large number of other unreacted first signal detection probes m1 / S1 in the reagent to enter the next cycle process. The second signal detection probe and the second signal amplification probe H2 adopt the same DNA base design concept as mentioned above and realize the second target miRNA signal detection and amplification, which will not be repeated here.
[0023] Taking miRNA-183 and miRNA-96, a group of markers that can characterize bladder cancer, as an example, a group of preferred sequence designs of the DNA sequences involved in the specific miRNA marker activity detection kit are as follows:
[0024] Ru-ss: 5′HS-SH-ATTACGCCGCGA-Ru(bpy)3 2+ -3′, sequence as SEQ ID NO.1;
[0025] Fc-ss: 5′Ferrocene-GTCAGCAGGGGG-3′, sequence as SEQ ID NO. 2;
[0026] Hp: 5′-CAACTTGGCGGTGGCAACCGCCCCCCCTGCTGACAACGGCGGCG-3′, sequence is SEQ IDNO.3;
[0027] S1: 5′-ACCGCCAAGTTGGTAGAATTC-3′, sequence as SEQ ID NO. 4;
[0028] S2: 5′-GTCAGCAGGGGGGGCGGTAGCACA-3′, sequence as SEQ ID NO.5;
[0029] m1: 5′-AGTGAATTCTACCAACTTCAGTGCCATA-3′, the sequence is as SEQ ID NO.6; H1: 5′-CAGTCGGCACTGAAGTTGGTAGAATTAC-3′, the sequence is as SEQ ID NO.7; m2: 5′-AGCAAAAATGTGCTACCGCCAGTGCCAAA-3′, the sequence is as SEQ ID NO.8; H2: 5′-AGTGTGGCACTGGCGGTAGCACATTGCT-3′, the sequence is as SEQ ID NO.9; the method for using the above detection kit comprises the following steps:
[0030] Step S1, obtaining a miRNA tumor marker sample;
[0031] Step S2, adding the target miRNA signal amplification reagent to the tumor marker sample to react and release the two signal activation chains;
[0032] Step S3, manufacturing an electrochemiluminescence sensor according to the above-mentioned preparation method of the electrochemiluminescence sensor;
[0033] Step S4, adding the product after the reaction in step S2 dropwise to the electrochemiluminescence sensor prepared in step S3, and incubating for 10 to 60 minutes, and more preferably 40 minutes;
[0034] Step S5, placing the electrochemiluminescent sensor after the reaction in step S4 in a PBS solution containing TPrA for electrochemical signal detection, and generating ECL signals in a 0.2-1.3V cyclic voltammetry scanning mode.
[0035] Beneficial effects:
[0036] Compared with the existing electrochemiluminescence detection dual-target platform, the ECL sensing platform provided by the present invention has a simple structure and can realize multi-target detection. The specific miRNA marker activity detection kit constructed by combining it with the target miRNA signal amplification reagent can be used for high-sensitivity parallel detection of low-concentration tumor markers, with high detection specificity, strong anti-interference ability, and good stability, reproducibility and regeneration. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] Figure 1a Schematic diagram of the construction process and detection principle of the ECL sensing platform of the present invention;
[0038] Figure 1b The toehold-mediated DNA strand displacement cyclic network reaction process of the present invention;
[0039] Figure 2 Flow chart of the UIO-66@AuNPs composite prepared according to a specific embodiment of the present invention;
[0040] Figure 3 TEM images and SEM images of the UIO-66@AuNPs composite prepared in the specific embodiment of the present invention, wherein Figure A is a TEM image of UIO-66 and UIO-66@AuNPs, and Figure B is a SEM image of UIO-66 and UIO-66@AuNPs;
[0041] Figure 4 This is an EDS elemental analysis diagram of the UIO-66@AuNPs composite prepared in a specific embodiment of the present invention;
[0042] Figure 5 The XRD pattern of the UIO-66@AuNPs composite prepared in the specific embodiment of the present invention;
[0043] Figure 6 This is the UV absorption spectrum of the UIO-66@AuNPs complex prepared in the specific embodiment of the present invention;
[0044] Figure 7 The Zeta potential diagram of the UIO-66@AuNPs complex prepared according to the specific embodiment of the present invention;
[0045] Figure 8 The DLS graphs of the UIO-66@AuNPs composite prepared in the specific embodiment of the present invention, wherein Figure A is the DLS graph of UIO-66, and Figure B is the DLS graph of UIO-66@AuNPs;
[0046] Fig. 9It is a PAGE representation diagram of the toehold-mediated DNA strand displacement cycle network and the DNA "AND" logic gate switch reaction process described in the specific embodiment of the present invention, wherein Figure A is a PAGE representation diagram of the DNA strand displacement cycle network, and Figure B is a PAGE representation diagram of the DNA "AND" logic gate switch reaction process;
[0047] Fig.10 This is an ECL curve representation diagram of the sensing platform construction process described in the specific implementation method of the present invention;
[0048] Fig.11 It is a CV curve characterization diagram of the sensing platform construction process described in the specific embodiment of the present invention;
[0049] Fig.12 The concentration of the substrate material UIO-66@AuNPs is optimized during the construction of the sensing platform described in the specific embodiment of the present invention;
[0050] Fig.13 In the process of constructing the sensing platform described in the specific embodiment of the present invention, the incubation time of the signal activation chain at the electrode interface is optimized;
[0051] Fig.14 It is the linear curve of ECL detection of miRNA of different concentrations according to the specific embodiment of the present invention, wherein Figure A and Figure B are the linear analysis of ECL detection of miRNA-183-5p of different concentrations, and Figure C and Figure D are the linear analysis of ECL detection of miRNA-96-5p of different concentrations;
[0052] Fig.15 The specificity of the ECL sensing platform for detecting miRNA in the specific embodiment of the present invention;
[0053] Fig.16 The ECL sensing platform described in the specific embodiment of the present invention detects the stability of miRNA;
[0054] Fig.17 The reproducibility of detecting miRNA by the ECL sensing platform described in the specific embodiment of the present invention;
[0055] Fig.18 The ECL sensing platform described in the specific embodiment of the present invention detects the reproducibility of miRNA;
[0056] Fig.19 This is the result analysis of the ECL sensing platform detecting real urine samples according to the specific embodiment of the present invention. DETAILED DESCRIPTION
[0057] In conjunction with the accompanying drawings, the detection process of the present invention is specifically described below using miRNA as a detection sample and a preferred ECL sensing platform, wherein the test materials and test equipment involved are as follows:
[0058] Zirconium oxychloride octahydrate (ZrOCl2·8H2O) and terephthalic acid (H2BDC) were purchased from Shanghai Aladdin Chemical Co., Ltd.; sodium borohydride (NaBH4) and tris(2-carboxyethyl)phosphine hydrochloride (TCEP) were purchased from Sigma; tripropylamine (TPA) was purchased from Shanghai Aladdin Chemical Co., Ltd. N,N-dimethylformamide (DMF) was purchased from Shanghai Yiang Chemical Technology Co., Ltd. All DNA oligonucleotides were synthesized and purified by Shanghai Shenggong Biotechnology Co., Ltd.; phosphate buffered saline (PBS, 0.1M, pH 7.4) containing 0.1M TPrA was used as the ECL working solution. All chemical reagents were analytically pure; the electrochemiluminescence analyzer was purchased from Xi'an Ruimai Company.
[0059] Example 1: Construction of ECL sensing platform
[0060] like Figure 1a As shown, in advance, the glassy carbon electrode was polished, ultrasonicated, and cleaned to obtain a clean electrode surface; 10 μL of an aqueous solution of UIO-66@AuNPs with a concentration of 2 mg / mL was dropped on the electrode, allowed to stand, and dried at room temperature; then, 10 μL of a pre-prepared TMbuffer solution containing a DNA "AND" logic gate switch structure with a concentration of 1 μM was dropped on the electrode, reacted at 4°C for 8 hours, and the structure was modified on the electrode using an Au-S bond, thereby preparing an ECL sensing platform.
[0061] Among them, Figure 2 As shown, a better preparation process of the UIO-66@AuNPs complex is as follows: UIO-66 is synthesized according to the method reported in the literature Metal Organic Framework-Based Bio-Barcode CRISPR / Cas12a Assay for Ultrasensitive Detection of MicroRNAs. Nano Lett. 2022, 22 (23), 9714-9722. Specifically, in this embodiment, 50 mg of terephthalic acid and 21 mg of ZrOCl2·8H2O are dissolved in 4 mL of N-N′-dimethylformamide (DMF), and then the mixture is ultrasonically oscillated, and 2 mL of acetic acid (HAc) is added, and heated at 90°C for 18 hours to obtain a UIO-66 solution, and then 20 μL of 1% concentration of chloroauric acid and 20 μL of freshly prepared 4 mg / mL sodium borohydride are added to the solution, and then stirred at 1200 rpm for 10 min, centrifuged to obtain UIO-66@AuNPs solid, which is dispersed in water and stored at low temperature.
[0062] like Figure 3 As shown, Figure A and Figure B are the TEM and SEM characterization images of the UIO-66 and UIO-66@AuNPs composites prepared above, respectively, where A1 and A2 are TEM characterization images of UIO-66, A3 and A4 are TEM characterization images of UIO-66@AuNPs, B1 is the SEM characterization image of UIO-66, and B2 is the SEM characterization image of UIO-66@AuNPs. The changes in morphology indicate that the gold particles are successfully loaded on UIO-66. The UIO-66 and UIO-66@AuNPs composites prepared above were analyzed by energy dispersive spectrometer EDS, as shown in FIG. Figure 4 The upper figure is the EDS analysis of UIO-66. From the elemental analysis results, it can be seen that it is mainly composed of C, O, and Zr elements; the lower figure is the EDS analysis of the UIO-66@AuNPs complex. From the elemental analysis results, it can be seen that it is mainly composed of C, O, Zr and Au elements, which further shows that the UIO-66@AuNPs complex was successfully prepared. In addition, X-ray diffraction (XRD) analysis proves the high crystallinity of the prepared MOF, which is not affected even after loading gold nanoparticles. Figure 5 At the same time, two new peaks corresponding to Au can be clearly identified in the spectrum. Figure 6 The UV absorption peak of the Au-loaded UIO-66 material at about 550 nm also showed a significant enhancement. Figure 7 The deposition of gold also resulted in a significant decrease in the Zeta potential from 57.1 mV to 2.7 mV, confirming the successful functionalization of AuNPs on UIO-66. Due to the high specific surface area of UIO-66, the deposition of gold particles on the surface of UIO-66 can effectively increase the loading capacity of subsequent DNA structures.
[0063] In addition, if Figure 8 As shown in Figure 3, the size distribution of the nanoparticles was measured by dynamic light scattering (DLS), and the results showed that the particle diameter increased from approximately 197.4 nm to 214.2 nm after gold deposition on the surface. This further indicates the successful integration of AuNPs on UIO-66.
[0064] Example 2 Construction and verification of DNA strand displacement network and DNA “AND” logic gate switch
[0065] The following sequences were designed and customized according to the sequences in the sequence table (manufactured by Shanghai Shenggong Biotechnology Co., Ltd.):
[0066] Ru-ss: 5′HS-SH-ATTACGCCGCGA-Ru(bpy)3 2+ -3′
[0067] Fc-ss: 5′Ferrocene-GTCAGCAGGGGG-3′
[0068] Hp: 5′-CAACTTGGCGGTGGCAACCGCCCCCCCTGCTGACAACGGCGGCG-3′
[0069] S1: 5′-ACCGCCAAGTTGGTAGAATTC-3′
[0070] S2: 5′-GTCAGCAGGGGGGGCGGTAGCACA-3′
[0071] m1: 5′-AGTGAATTCTACCAACTTCAGTGCCATA-3′
[0072] H1:5′-CAGTCGGCACTGAAGTTGGTAGAATTAC-3′
[0073] m2: 5′-AGCAAAAATGTGCTACCGCCAGTGCCAAA-3′
[0074] H2: 5′-AGTGTGGCACTGGCGGTAGCACATTGCT-3′
[0075] The feasibility of the designed DNA logic network was verified by 8% polyacrylamide gel electrophoresis (PAGE) experiment. Figure 1b The reaction process of the toehold-mediated DNA strand displacement network is demonstrated. Fig. 9 Figure A in the figure is the corresponding PAGE characterization result. The PAGE bands observed in lanes 2-5 indicate the presence of four separate chains involved in the reaction process. The higher position of the band in lane 6 indicates a double-stranded structure (m1 / S1) containing the signal activation chain, which is consistent with the meaning of the band at the same position in lane 8. In the presence of miRNA, a miRNA / m1 structure with more base pairs is formed, resulting in the release of the signal activation chain S1 (lane 7). Lane 8 represents a system without miRNA, in which the product consists only of m1 / S1 and H1. Finally, the complete DNA chain displacement network process was verified, and the highest position band in lane 9 indicates the presence of the final product (m1 / H1) in the reaction, thereby reliably verifying the successful implementation of the chain displacement reaction. Fig. 9Figure B in Figure 2 shows the structure and feasibility evaluation of the DNA AND logic gate switch. The bands observed in lanes 2, 3, and 4 represent the three single strands that constitute the AND logic gate, respectively. Lanes 5 and 6 depict the two signal activation strands. The bands observed in lane 7 demonstrate the successful construction of the DNA logic gate. In lanes 8 and 9, S1 and S2 were introduced into the DNA logic gate, respectively. The verification results of the AND logic are visually depicted by the band positions. When only S1 was added, the hairpin DNA in the logic structure unfolded, resulting in its position slightly higher than that of the logic gate. However, in channel 9, the addition of S2 alone did not affect the overall structure of the logic gate, as evidenced by the unchanged band position. Finally, the overall reaction process of the DNA AND logic gate switch was simulated. When S1 and S2 were introduced, a new band appeared in channel 10, indicating the formation of the expected structure. In addition, this confirmed the desired result that the signal quenching strand was replaced to produce a higher ECL signal, and the DNA AND logic signal only appeared when the two signal activation strands were present at the same time.
[0076] The construction process of the ECL sensing platform was characterized by ECL and CV. Fig.10 are the ECL curves of different modification processes. Fig.11 CV of different modification processes, where a represents a bare electrode, b represents an electrode surface modified with UIO-66@AuNPs, c represents a DNA “AND” logic gate switch structure modified on the basis of b, d represents the addition of a signal activation chain S1 to the sensing platform, and e represents the addition of a signal activation chain S2 on the basis of d. The changes in the ECL signal and the current of the CV curve indicate the successful preparation of the sensing platform.
[0077] Test Example 1: Comparison of the relationship between the concentration of UIO-66@AuNPs and the signal intensity of the ECL sensing platform
[0078] The concentration of UIO-66@AuNPs was optimized as the substrate material, and the concentrations investigated were: 0.1 mg / mL, 0.2 mg / mL, 0.4 mg / mL, 1 mg / mL, 2 mg / mL, 4 mg / mL, and 8 mg / mL, respectively. The other preparation conditions were the same as in Example 1, and an ECL sensing platform based on different concentrations of UIO-66@AuNPs was prepared. Then the prepared ECL sensing platform and the signal activation chain were incubated at the electrode interface for 1 hour at room temperature. The concentrations of the signal activation chains S1 and S2 were both 1 μM; the incubated ECL sensing platform was used to detect the ECL signal, and the detection conditions and parameters of the ECL signal were as follows: the ECL sensing platform was used as the working electrode, the Ag / AgCl electrode was used as the reference electrode, the Pt wire was used as the auxiliary electrode, and the cyclic voltammetry scanning voltage was used. The voltage range was 0.2-1.3 V, the scanning speed was 0.1 V / s, and the photomultiplier tube high voltage was 800 V; the detection results are as follows Fig.12 As shown, with the gradual increase of the concentration of UIO-66@AuNP material, the luminescence intensity gradually increased, and the signal reached the maximum at 2 mg / mL, indicating that when the concentration of UIO-66@AuNP was 2 mg / mL, the amount of loaded DNA logic gate switch reached saturation.
[0079] Test Example 2: Comparison of the relationship between the incubation time of the signal activation chain at the electrode interface and the signal intensity of the ECL sensing platform
[0080] The incubation time of the signal activation chain at the electrode interface was optimized, and the investigation times were: 10 min, 20 min, 30 min, 40 min, and 60 min. In this test example 2, except for the different incubation time and the fixed concentration of UIO-66@AuNPs as the substrate material being 2 mg / mL, the other conditions were the same as those in test example 1. Fig.13 As shown, as the incubation time gradually increases, the luminescence intensity gradually increases, and the signal reaches the highest at 40 minutes. Based on the test results of Test Example 1 and Test Example 2, 2 mg / mL of UIO-66@AuNP and 40 minutes of incubation time are selected as the optimal reaction conditions.
[0081] Test Example 3: Detection Limit Analysis of miRNA-183-5p and miRNA-96-5p Activity Detection
[0082] The ECL sensing platform constructed in Example 1 and the target miRNA signal amplification reagent formed in Example 2 were used as the detection system to detect the activity of the target miRNA-183-5p and miRNA-96-5p. In this test, different concentrations of miRNA-183-5p and miRNA-96-5p (1fM, 10fM, 100fM, 1pM, 10pM, 100pM) were detected respectively. Specifically, Fig.14 The ECL signal curves associated with different concentrations of miRNA-183-5p in the experiment are based on the following detection conditions: the miRNA-183-5p sample and its corresponding target miRNA signal amplification reagent are subjected to a strand displacement reaction at room temperature for 2 hours; the reaction mixture is then incubated with S2 at a fixed concentration of 1 μM and the constructed ECL sensing platform at room temperature for 40 minutes; the detection conditions and parameters of the ECL signal are the same as those in Test Example 1;
[0083] Accordingly, Fig.14 The ECL signals associated with different concentrations of miRNA-96-5p in the experiment are based on the following detection conditions: the miRNA-96-5p sample and its corresponding target miRNA signal amplification reagent are subjected to a strand displacement reaction at room temperature for 2 hours; the reaction mixture is then incubated with S1 at a fixed concentration of 1 μM and the constructed ECL sensing platform at room temperature for 40 minutes; the detection conditions and parameters of the ECL signal are the same as those in Test Example 1;
[0084] Fig.14 The linear relationship was shown, and the ECL intensity had a good correlation with the miRNA concentration in the range of 1fM to 100pM, with a correlation coefficient R 2 The relative molecular weights were 0.991 and 0.996, respectively, and the detection limits were 0.45 fM and 0.85 fM, respectively.
[0085] Test Example 4: miRNA sequence interference test
[0086] In order to evaluate the specificity of the proposed dual-target sensing detection system, miR-27a was selected as interference. Except for the different detection targets, the other detection conditions were the same as those of test case 3;
[0087] like Fig.15As shown, when miR-27a at a concentration of 1 μM was used as one of the targets, i.e., test group ② or test group ③, the ECL reaction was similar to that obtained in the blank sample, i.e., blank test group ①, while the ECL signal of miR-183-5p at a concentration of 0.1 μM and S2 at a concentration of 1 μM, i.e., test group ④, was significantly stronger. It is worth noting that even in the presence of interference, i.e., test group ⑤: miRNA-27a at a concentration of 1 μM, miRNA-183-5p at a concentration of 0.1 μM, and S2 at a concentration of 1 μM, the sensing platform showed extraordinary specificity and produced accurate results despite its concentration being ten times higher than the target. This demonstrates the excellent specificity of the sensing platform in detecting dual targets. It is worth noting that the similarity between miRNA sequences imposes strict requirements on the specificity of nucleic acid sensors. Therefore, experiments were conducted on the sensor platform using the mismatch sequences of the single-base test group ⑥ and the double-base test group ⑦ of miR-183-5p. Specifically, the mismatch sequence of the test group ⑥ is shown in SEQ ID NO.12, specifically: 5′-UAUGGGACUGGUAGAAUUCACU-3′; the mismatch sequence of the test group ⑦ is shown in SEQ ID NO.13, specifically: 5′-UAUGGGACUGGUAGAAUUGACU-3′;
[0088] Experimental evidence showed that base mismatches could generate signals slightly above background, which were nonetheless significantly lower than the signal from the target. This result confirmed the ability of the ECL sensing platform to accurately distinguish between correct sequences and sequences with base mutations, thus highlighting its superior specificity.
[0089] Test Example 5: Stability, Reproducibility and Regeneration of the Detection System Based on the ECL Sensing Platform
[0090] The stability of the proposed sensing detection system was then evaluated. 10pM miR-183-5p was selected as the sample. The other conditions were the same as those in Test Example 3. Ten cycles of continuous potential scanning were performed on the ECL sensing platform. During the whole process, the concentration of signal activation chain S2 was kept constant at 1μM. Fig.16 As shown, the relative standard deviation (RSD) was found to be 1.72%, which indicates that the proposed ECL sensing platform has an exceptional stability.
[0091] In addition, a reproducibility experiment was performed to study the performance of the ECL biosensor. Five replicate ECL sensing platforms with the same preparation conditions were prepared, all used to detect 0.1 pM miR-183-5p, and the test process was the same as in Test Example 3; Fig.17 As shown in Figure 2, the test results showed an RSD of 4.8%, demonstrating the commendable reproducibility of the ECL biosensor. Figure 1a ,include:
[0092] As shown in SEQ ID NO. 14 cS1: 5′-GAATTCTACCAACTTGGCGGT-3′;
[0093] As shown in SEQ ID NO. 15 cS2: 5′-TGTGCTACCGCCCCCCCTGCTGAC-3′
[0094] and the signal quenching chain Fc-ss, realizing the regeneration of the sensing platform. Fig.18 It was shown that under the optimized experimental conditions, the ECL signal generated by the sensing platform could be relatively maintained at 95.1% even after three regeneration operations, demonstrating the excellent regeneration ability of the biosensor.
[0095] Test Example 6: Target Detection in Human Urine
[0096] To evaluate the reliability and utility of the ECL sensing platform for detecting dual miRNAs in complex biological samples, miRNA detection was performed in human urine. The miRNAs extracted from urine samples of early-stage cancer patients (n = 10) and healthy individuals (n = 10) were analyzed separately. First, a miRNA extraction kit (purchased from Nanjing Borez Biotechnology Co., Ltd., model BLOODmisi whole blood (liquid sample) microRNA rapid extraction kit) was used to extract miRNA concentrate from the urine sample. When quantitatively detecting miRNA-183-5p, the concentrate was added to the first group of signal amplification reagents in Example 2. The corresponding signal detection probes and signal amplification probe concentrations were set to 1 μM. After fully reacting at room temperature for two hours, the product was added to the pre-modified electrochemiluminescence sensing platform. After reacting at room temperature for 40 minutes, the electrode interface was washed with PBS buffer, and then a signal activation chain S2 with a concentration of 1 μM was added. The reaction was again carried out at room temperature for 40 minutes. After washing with PBS buffer, the electrochemiluminescence signal of the electrode was detected. The same group of samples was detected three times in parallel with three electrodes, and the obtained electrochemiluminescence signal was then converted from a linear relationship to the concentration of the corresponding detection target. The same method was used for the quantitative detection of miRNA-96-5p, which will not be elaborated here. Fig.19 It can be seen that the levels of miR-183-5p and miR-96-5p in the urine of bladder cancer patients were significantly higher than those of healthy people. In addition, the average expression levels of these two miRNAs were able to effectively distinguish bladder patients from healthy individuals. The results showed that the constructed sensing platform can achieve preliminary screening of cancer patients by detecting two urine biomarker miRNAs in parallel.
Claims
1. An ECL sensing platform, the ECL sensing platform is an electrochemiluminescence sensor, It is characterized in that The electrochemiluminescent sensor is composed of a sensing substrate and a DNA "AND" logic gate switch complex loaded on the sensing substrate; the sensing substrate is composed of a glassy carbon electrode and a substrate material UIO-66@AuNPs modified on the glassy carbon electrode; the DNA "AND" logic gate switch complex is a complex formed by hybridization of an Hp chain, an Fc-ssDNA chain and a Ru-ss chain, wherein the Hp chain is a DNA chain containing a hairpin structure, the Fc-ssDNA chain is a single chain modified with a quenching group ferrocene; the Ru-ss chain is a single chain modified with a luminescent group Ru(bpy) 3 2+ and a single strand having a thiol functional group; the DNA "AND" logic gate switch complex is specifically opened by two signal activation strands; The modified thiol functional group on the Ru-ss chain is loaded on the UIO-66@AuNPs through the Au-S covalent bond, and the ferrocene and the luminescent group Ru(bpy) 3 2+ There is a signal quenching effect between them; Among them, the activation chain S1 can open the hairpin structure of the Hp chain and bind to it. After the hairpin structure of the Hp chain is opened, the exposed block can enable the activation chain S2 to replace the Fc-ssDNA chain and the Hp chain to form a more stable structure, so that the signal of the luminescent group can be detected; The preparation process of UIO-66@AuNPs includes: terephthalic acid and ZrOCl 2 8H 2 O was dissolved in NN′-dimethylformamide, and then the mixture was ultrasonically shaken, acetic acid was added, and heated at 90°C for 18 hours to obtain UIO-66 solution. Then, 1% chloroauric acid and freshly prepared sodium borohydride were added to the solution, and then centrifuged to obtain a solid composite UIO-66@AuNPs, which was dispersed in water and stored at low temperature; The Hp chain is a DNA chain containing multifunctional blocks which is sequentially composed of block Hp-1, block Hp-2, block Hp-3, Hp-4, Hp-5 and Hp-6, wherein the sequences of block Hp-2 and block Hp-4 are complementary to each other to form a hairpin structure, the DNA sequence of the Fc-ssDNA chain is complementary to block Hp-5, and the DNA sequence of the Ru-ss chain is complementary to block Hp-6; the sequence composed of block Hp-1 and block Hp-2 is complementary to the activation sequence S1-1 of the activation chain S1, the hairpin structure of the Hp chain is opened by the activation chain S1 to expose blocks Hp-3 and Hp-4, the sequence composed of blocks Hp-4 and Hp-5 is complementary to the activation sequence S2-1 of the activation chain S2, and the activation chain S2 can replace the Fc-ssDNA chain to form a more stable structure with the Hp chain, and the DNA base sequence in Ru-ss is as shown in SEQ ID NO .1, the DNA base sequence in Fc-ss is shown in SEQ ID NO.2; the DNA base sequence of Hp is shown in SEQ ID NO.3; the DNA base sequence of the activation sequence S1-1 is shown in SEQ ID NO.10; and the DNA base sequence of the activation sequence S2-1 is shown in SEQID NO.
11.
2. The method for preparing the ECL sensing platform according to claim 1, It is characterized in that The preparation method comprises the following steps: in advance, grinding, ultrasonicating and cleaning a glassy carbon electrode to obtain a clean electrode surface; dropping an aqueous solution of UIO-66@AuNPs on the electrode, standing it, and drying it at room temperature; then dropping a TM buffer solution of the DNA AND logic gate switch complex on the electrode, reacting it at 4°C for 8 hours, and modifying the structure on the electrode using an Au-S bond to obtain the ECL sensing platform, wherein the concentration range of the aqueous solution of UIO-66@AuNPs is 0.1-8 mg / mL.
3. The preparation method according to claim 2, It is characterized in that The concentration of the aqueous solution of UIO-66@AuNPs is 2 mg / mL.
4. Use of the ECL sensing platform according to claim 1 in preparing a specific miRNA marker activity detection kit, It is characterized in that The specific miRNA marker is a group of combined markers that can specifically characterize a specific type of disease, including a first target miRNA and a second target miRNA, and the sequence length of the first target miRNA and the second target miRNA is within the range of 21-23 bases; The detection kit is composed of the above-mentioned ECL sensing platform and a target miRNA signal amplification reagent; the target miRNA signal amplification reagent is a mixed reagent composed of a toehold-mediated DNA strand displacement cycle network; The activation chains S1 and S2 also respectively contain a release sequence designed according to the sequence of the target miRNA, which are marked as S1-2 and S2-2 respectively, that is, block S1-2 is designed according to the sequence of the first target miRNA, and block S2-2 is designed according to the sequence of the second target miRNA; the target miRNA signal amplification reagent is composed of two groups of signal amplification reagents, the first group of signal amplification reagents is used to amplify the signal of the first target miRNA, and the second group of signal amplification reagents is used to amplify the signal of the second target miRNA; the first group of signal amplification reagents is composed of a first signal detection probe and a first signal amplification probe, the first signal detection probe is a DNA structure m1 / S1 formed by hybridization of m1 and S1, and the first signal amplification probe H1 is a DNA chain with hairpin structures at both ends; correspondingly, the second group of signal amplification reagents is composed of a second signal detection probe and a second signal amplification probe, the second signal detection probe is a DNA structure m2 / S2 formed by hybridization of m2 and S2, and the second signal amplification probe H2 is also a DNA chain with hairpin structures at both ends; The first signal detection probe and the second signal detection probe specifically respond to two target miRNAs, thereby releasing two signal activation chains S1 and S2; the first signal amplification probe H1 and the second signal amplification probe H2 are respectively complementary to the two single-stranded m1 and m2 parts, and can hybridize with S1 and S2 after they are released, thereby releasing the target miRNA; the two large signal activation chains released by the toehold-mediated DNA chain displacement cycle network can specifically open the DNA "AND" logic gate switch.
5. The use according to claim 4, It is characterized in that The DNA bases of the first signal detection probe and the first signal amplification probe H1 are designed as follows: in the first signal detection probe, the single strand m1 is composed of blocks m1-1, m1-2, and m1-3 in sequence; the sequence m1-1-2 composed of the blocks m1-1 and m1-2 is complementary to S1-1, but the sequence m1-1-2 is slightly longer than S1-1, i.e., it has 4 more bases. After the two are complementary, the sequence m1-1-2 still has a free sticky sequence; the block m1-3 is complementary to S1-2, but the sequence m1-3 is slightly longer than S1-2, i.e., it has 3 more bases. After the two are complementary, the sequence m1-3 still has a free sticky sequence, and the single strand m1 has only The sequence composed of blocks m1-1 and m1-3 is completely complementary to the first target miRNA. The first signal amplification probe H1 is composed of blocks H1-1, H1-2 and H1-3 in sequence, wherein the internal sequences of blocks H1-1 and H1-3 are complementary to form a neck ring structure at both ends of H1, and only the middle H1-2 is exposed and can be specifically recognized by m1-2. Blocks H1-1 and H1-3 contain sequences complementary to m1-1 and m1-3, respectively. The second signal detection probe and the second signal amplification probe H2 adopt the same DNA base design principles as mentioned above to achieve second target miRNA signal detection and amplification.
6. The use according to claim 4, It is characterized in that The specific miRNA markers are a group of markers characterizing bladder cancer, namely miRNA-183 and miRNA-96. The DNA base sequence of Ru-ss is shown in SEQ ID NO.1; the DNA base sequence of Fc-ss is shown in SEQ ID NO.2; the DNA base sequence of Hp is shown in SEQ ID NO.3; the DNA base sequence of S1 is shown in SEQ ID NO.4; the DNA base sequence of S2 is shown in SEQ ID NO.5; the DNA base sequence of m1 is shown in SEQ ID NO.6; the DNA base sequence of H1 is shown in SEQ ID NO.7; the DNA base sequence of m2 is shown in SEQ ID NO.8; and the DNA base sequence of H2 is shown in SEQ ID NO.
9.
7. The use according to claim 4, It is characterized in that The method for using the detection kit comprises the following steps: step S1, obtaining a miRNA tumor marker sample; step S2, adding the target miRNA signal amplification reagent to the tumor marker sample for reaction to release two signal activation chains; step S3, preparing an electrochemiluminescence sensor according to the preparation method of the electrochemiluminescence sensor; step S4, dropping the product after the reaction in step S2 onto the electrochemiluminescence sensor prepared in step S3, and incubating for 10 to 60 minutes; step S5, placing the electrochemiluminescence sensor after the reaction in step S4 in a PBS solution containing TPrA for electrochemical signal detection, and generating an ECL signal in a 0.2 to 1.3 V cyclic voltammetry scanning mode.
8. The use according to claim 7, It is characterized in that In step S4, the incubation time is 40 min.
Citation Information
Patent Citations
MiRNA tumor marker detection kit
CN115032258A
Group selective functionalization potential resolution type electrochemical luminescence nucleic acid detection method
CN116297769A
Electrochemical sensor based on DNA configuration transformation
CN105784809A
Construction method for hairpin DNA supported dual-signal molecular sensing interface and application of sensing interface
CN105973963A
Dual-amplification ECL biosensor based on triple-helix molecular switch ultra-sensitive measurement LPS and application thereof
CN110274948A
